Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374796 · ClinicalTrials.gov registry record
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
A clinical trial, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- 450
- Enrollment target
NCT07374796: Clinical Trial study, sponsored by University of Maryland, Baltimore.
NCT07374796 is a clinical trial that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 450 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07374796 has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- 450 participants
- Enrollment target
Study Summary
The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Primary Outcome
Genome-wide methylation profile of whole blood from lung cancer patients, pre-cancer patients, patients undergoing therapy, and control subjects.
Interventions
- OTHER Epigenetic Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-07 |
What is known before NCT07374796 opens enrollment
NCT07374796 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Epigenetic Assay is the first listed.
NCT07374796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07374796 about?
NCT07374796 is a clinical study titled "Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer". The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samp...
What is the current status of trial NCT07374796?
This trial is currently not yet recruiting. The enrollment target is 450 participants. The study started on 2026-06-01. Estimated completion is 2032-07.
What interventions are being tested in trial NCT07374796?
The interventions under investigation include: Epigenetic Assay (OTHER).
Who is sponsoring clinical trial NCT07374796?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI